公开(公告)号：US20050065075A1

公开(公告)日：2005-03-24

申请号：US10478811

申请日：2002-05-31

申请人： John Erickson ,  Dominique Bridon ,  Martin Robitaille ,  Grant Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

发明人： John Erickson ,  Dominique Bridon ,  Martin Robitaille ,  Grant Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

IPC分类号： A61K47/48 ,  A61K38/00 ,  A61P31/14 ,  A61P31/18 ,  C07K1/113 ,  C07K14/00 ,  C07K14/16 ,  A61K38/16 ,  C07K14/47

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K2319/00 ,  C12N2740/16122

摘要： The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

摘要翻译： 本发明涉及作为病毒感染抑制剂和/或显示抗融合性质的C34肽衍生物。 特别地，本发明涉及具有长期持续时间的针对人免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV））具有抑制活性的C34衍生物 的治疗各自病毒感染的作用。

公开(公告)号：US07741453B2

公开(公告)日：2010-06-22

申请号：US10478811

申请日：2002-05-31

申请人： John W. Erickson ,  Dominique P. Bridon ,  Martin Robitaille ,  Grant A. Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

发明人： John W. Erickson ,  Dominique P. Bridon ,  Martin Robitaille ,  Grant A. Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

IPC分类号： C08H1/00

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K2319/00 ,  C12N2740/16122

摘要： The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

摘要翻译： 本发明涉及作为病毒感染抑制剂和/或显示抗融合性质的C34肽衍生物。 特别地，本发明涉及具有长期持续时间的针对人免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV））具有抑制活性的C34衍生物 的治疗各自病毒感染的作用。

公开(公告)号：US20110166061A1

公开(公告)日：2011-07-07

申请号：US12767646

申请日：2010-04-26

申请人： John W. Erickson ,  Dominique P. Bridon ,  Martin Robitaille ,  Grant A. Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra De Meyer

发明人： John W. Erickson ,  Dominique P. Bridon ,  Martin Robitaille ,  Grant A. Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra De Meyer

IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P31/18

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K2319/00 ,  C12N2740/16122

摘要： The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

摘要翻译： 本发明涉及作为病毒感染抑制剂和/或表现出抗融合性质的C34肽衍生物。 特别地，本发明涉及具有长期持续时间的针对人免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV））具有抑制活性的C34衍生物 的治疗各自病毒感染的作用。

公开(公告)号：US20220323353A1

公开(公告)日：2022-10-13

申请号：US17620167

申请日：2019-06-19

申请人： Elena AFONINA ,  Hiep DO ,  Emily GOEL ,  Oleg GURYEV ,  Cyal LECY ,  Majid MEHRPOUYAN ,  Michael RANDALL ,  Marybeth SHARKEY ,  Jeffrey WANG ,  Becton, Dickinson and Company

发明人： Elena Afonina ,  Hiep Q Do ,  Emily Goel ,  Oleg Guryev ,  Cyal Lecy ,  Majid Mehrpouyan ,  Michael Randall ,  Marybeth Sharkey ,  Jeffrey Wang

IPC分类号： A61K9/127 ,  A61K9/16 ,  A61K31/704 ,  A61K31/44

摘要： Drug-loaded microbead compositions including a plurality of individual microbeads of a biodegradable material, a plurality of individual vesicular agents, a first therapeutic agent, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include at least one lipid bilayer surrounding a vesicular core. The first therapeutic agent is associated with the individual vesicular agents. For example, the first therapeutic agent may be contained within the individual vesicular agents or may be associated with the individual vesicular agents by ionic or non-covalent interaction. The second therapeutic agent is different from the first therapeutic agent and contained within the individual microbeads or associated with the individual microbeads through ionic or non-covalent interaction. The second therapeutic agent may or may not be associated with the individual vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent associated with N the microbeads.

公开(公告)号：US20070207952A1

公开(公告)日：2007-09-06

申请号：US10550715

申请日：2004-03-24

申请人： Abelardo Silva ,  John Erickson ,  Michael Eissenstat ,  Elena Afonina ,  Sergei Gulnik

发明人： Abelardo Silva ,  John Erickson ,  Michael Eissenstat ,  Elena Afonina ,  Sergei Gulnik

IPC分类号： A61K38/16 ,  A61K38/10 ,  C07K14/47 ,  C07K7/08

CPC分类号： C07K14/765 ,  A61K38/00 ,  A61K47/643

摘要： The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

摘要翻译： 本发明提供可与大分子如白蛋白反应的生物活性化合物以形成共价连接的络合物，其中所得的复合物在体内显示出所需的生物学活性。 更具体地，复合物是包含与连接基团和蛋白质共价结合的生物活性部分的分离的复合物。 通过将生物活性部分例如肾素抑制剂或病毒融合抑制剂肽与纯化和分离的蛋白质缀合来制备复合物。 与非共轭分子相比，复合物在血液中的寿命延长，与非共轭分子相比，延长的时间段具有生物活性。 本发明还提供了抗病毒化合物，其是病毒感染的抑制剂和/或表现出抗融合生物学特性。 特别地，本发明提供了对人体免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV）等病毒具有抑制活性的化合物， 延长了治疗病毒感染的时间。